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Abstract 
This study aimed at exploring the link between individual concentrations, pharmacokinetic 
parameters and the probability of relapse after de-escalation in a real-world prospective 
cohort of IBD patients who underwent infliximab treatment de-escalation. Ninety-one 
patients were included. A time-varying compartment model was used to estimate individual 
pharmacokinetic parameters and trough concentrations. A Cox model was implemented to 
explore the parameters influencing the probability of relapse after de-escalation. Volume, 
clearance, and trough before and after de-escalation were linked to the relapse risk at the 
univariate step. Independent predictors of relapse were tobacco use and/or ulcerative colitis 
(p=0.0093), a higher C-Reactive Protein (p=0.00064), an infliximab trough <2.4 µg/mL after 
de-escalation (p=0.0001). Patients with trough >5.7µg/mL are eligible to de-escalation, but 
infliximab pharmacokinetics is highly variable in time. Therefore, drug monitoring is 
mandatory after de-escalation to maintain trough >2.4µg/mL. Clearance monitoring seem an 
appealing approach for patient selection and relapse prediction. 
 
1. Introduction
Infliximab is a chimeric murine-human monoclonal IgG1 that targets circulating and tissue 
human Tumour Necrosis Factor  (TNF). It has proven effective in the management of 
chronic Inflammatory Bowel Diseases (IBD), namely Crohn’s Disease (CD) and Ulcerative 
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Colitis (UC)1. However, the use of infliximab is associated with an increased risk of cancer, 
lymphoma and opportunistic infections2,3, raising the question of how to reduce these risks 
in patients with long-term maintenance infliximab treatment. Drug discontinuation has been 
proposed but led to a high relapse rate4-7. Alternatively, treatment de-escalation by lowering 
the dose or increasing the interval between infusions allows decreasing drug’s exposure 
while maintaining efficacy. Recent data support the relevancy of de-escalation, as higher 
infliximab levels were reported to be linked to an increased risk of infections8. However, 
data regarding the predictive factors of maintenance of the response after de-escalation of 
infliximab in IBD are sparse. Amiot and colleagues reported that discrepancies between blind 
(i.e., based only on clinical data and C-Reactive Protein [CRP]) and therapeutic drug 
monitoring (TDM)-based dose adjustments led to poorer outcomes after de-escalation9. 
More recently, we demonstrated that TDM-guided selection of the patients before de-
escalation led to a lower risk of relapse10. In this retrospective study, the TDM-based 
selection of the patients laid on a minimal value of 7µg/mL before de-escalation, as in the 
literature11 and in accordance with the current knowledge of infliximab pharmacokinetics. 
However, trough concentrations were not available in all the patients and we were unable to 
assess the predictive value of the trough concentration on the de-escalation outcomes, 
neither to determine an optimal concentration threshold of infliximab before and/or after 
de-escalation associated with a lower relapse rate. Furthermore, no data are available 
regarding the predictive value of individual pharmacokinetic characteristics on the 
probability of success of the de-escalation. Identifying these pharmacokinetic characteristics 
seems an appealing approach, because they are closely linked to the activity of the disease, 
and recent data suggest that monitoring of infliximab clearance along with the 
concentrations may be superior to concentrations alone in predicting the success of the 
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treatment12. Moreover, the long-term pharmacokinetics of infliximab has never been 
described in IBD patients with sustained remission who underwent a de-escalation, though 
infliximab pharmacokinetics may be different in this population compared to patients with 
an active disease, with a direct impact on the modalities of dose adjustments. The use of 
population pharmacokinetic modelling can help address these questions and refine the 
exploration of the predictive factors of relapse at de-escalation. 
This study aimed at (i) describing the long-term pharmacokinetics of infliximab in a real-
world cohort of adults with IBD in deep remission who underwent a de-escalation, and (ii) 
exploring whether pharmacokinetic parameters and infliximab trough concentrations were 
associated with successful de-escalation. 
 
2. Results
2.1. Study population 
The study included 91 patients followed up between 2012 and 2017, with a median (IQR) 
follow-up time of 3.75 (2.79 – 4.82) years. Overall, 155 infliximab de-escalation and 44 
relapses were recorded. A single de-escalation was performed in 43 patients (47.3%), 36 
patients (39.6%) experienced 2 de-escalations, and 12 patients (13.1%) had more than 2 de-
escalations during their follow-up; 38 patients (40.9%) experienced 1 relapse, and 4 (4.3%) 
experienced more than 1 relapse. The median (IQR) time to relapse (all confounded) was of 
280 (190 – 416) days after de-escalation. The characteristics of the subjects are summarized 
in table 1. 
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2.2. Pharmacokinetic analysis 
A total of 607 infliximab concentrations were used to build the pharmacokinetic model. A 
one-compartment model with time-varying clearance predicted the data well. 
The screening of the time-varying covariates revealed that infliximab clearance increased 
with body weight (p<0.0001), CRP (p=0.0017), and disease activity (p=0.00022). The 
influence of the activity was however quantifiable only in UC patients. Azathioprine co-
treatment was associated with a slower clearance and was also included as a time-varying 
covariate in the model (p=0.0018). Overall, 54 increases in infliximab dose were recorded in 
44 patients, which were strongly associated with clearance variations (difference in the 
Objective Function Value [OFV] =-23.1, p<0.0001). In a typical patient, there was a decrease 
in the clearance of infliximab of 16.9% when increasing the dose from 5 to 10 mg/kg. All 
these covariates were retained in the model with an overall OFV of -93.2 compared to the 
base model (table 2). 
The addition of a linear increase of the clearance with time (denoted to as ) greatly 
improved the full time-varying covariates model (OFV=-75.4), but resulted in the effect of 
body weight on clearance not being significant anymore, probably indicating a redundancy 
of  and body weight in describing intra-individual clearance variation. 
The majority of the remaining concentrations that were not well predicted were properly 
described after the addition a logit-risk model as previously described12, with a decrease of 
Akaike's Information Criterion (AIC) of -64. Of note, only 1 sample was tested positive to 
Anti-Drug Antibodies (ADA) and thus the effect of this covariate was not assessed. 
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Eventually, the screening of the static covariates revealed a higher clearance in UC patients 
(p=0.00023). Because the patients were followed over a long period, some of them had 
important changes of their corpulence consecutively to disease improvement or worsening. 
A linear mixed effect model was built to determine the slope of the body weight variations 
with time over the observation period. The slope of body weight variation partially explained 
the interindividual variability of the linear increase in clearance (decrease of the unexplained 
variability of  from 29.9% to 18.8%, p=0.0012). 
The diagnostic plots showed no obvious model misspecification or bias (figure 1), as well as 
the Visual Predictive Checks (VPCs) (figure 2). Some typical individual fits are presented in 
figure 3, with a representation of the evolution of the clearance with time. 
 
2.3. Study of the predictive factors of de-escalation outcome 
In the univariate analysis, the probability of relapse after infliximab de-escalation was not 
influenced by treatment history, demographics or biologics, apart from the CRP which 
increasing value at the time of the de-escalation increased the risk of subsequent relapse 
(p=0.0019). Smokers had a higher risk of relapse (p=0.012). The disease type did not 
influence the probability of relapse, but further investigations revealed that the combined 
effects of smoking status and disease were linked to the probability of relapse, with a higher 
risk in smoking CD patients (p=0.0026) and non-smoking UC patients (p=0.021). After 
gathering the groups with comparable risks, UC patients (whatever the smoking status) and 
smoking CD patients had a significant higher risk of relapse after de-escalation (p=0.0031, 
figure 4). Conversely, a younger age at diagnosis was slightly associated with a decreased risk 
of relapse (p=0.047). 
A
cc
ep
te
d
 A
rt
ic
le
. 
Regarding the pharmacokinetic parameters, a higher volume of distribution was associated 
with a decreased risk of relapse (p=0.0075), and a higher individual clearance at the time of 
the de-escalation was associated with poorer outcomes (p<0.0001). Optimal discriminating 
thresholds were found at 11.3L (p=0.0008) and 0.31L/d (p=0.0005), respectively (figure 4). In 
total, 2254 trough concentrations were estimated, with a median (IQR) value of 8.0 (4.2 – 
14.9) µg/mL. The probability of relapse increased with infliximab levels at de-escalation 
(p=0.014), with an optimal discriminating threshold of <5.7 µg/mL at trough just before de-
escalation being strongly predictive of the risk of relapse after de-escalation (p<0.0001, 
figure 4). The mean trough concentration calculated from the first trough after de-escalation 
to the censoring time was also predictive of the risk of relapse of the de-escalation, with an 
optimal discriminating threshold of 2.4 µg/mL (p<0.0001, figure 4). 
After backward selection of the variables, the CRP value at de-escalation, the combined 
disease/smoking status and the average trough of infliximab after de-escalation were 
retained as independent predictors of the success of de-escalation (table 3). 
 
3. Discussion
This study described the long-term pharmacokinetics of infliximab in adult IBD patients using 
a time-varying model, emphasizing the wide inter- and intra-individual variability of the 
clearance over an extended follow-up period. Moreover, this is the first population 
pharmacokinetic study to focus on treatment de-escalation. Our results show that infliximab 
concentrations and individual pharmacokinetic parameters are strongly associated with the 
clinical outcome after de-escalation. 
A
cc
ep
te
d
 A
rt
ic
le
. 
The values of the estimated pharmacokinetic parameters are in accordance with previous 
compartment pharmacokinetic studies in adults13-16. The data were best described by a one-
compartment model with linear elimination. This was expected with a dataset constituted 
mainly from trough concentrations, which precluded the identification of the distribution 
process and of the non-linear component of infliximab clearance. 
Monoclonal antibodies display a target-mediated elimination. For anti TNF antibodies such 
as infliximab, this implies that the subjects with an active disease producing high amounts of 
TNF have a faster clearance than the patients in remission. Inversely, the blockade of the 
effects of TNF by infliximab induces a decrease in the disease-related inflammation, a 
consecutive decrease in the production of TNF, and ultimately result in a decrease in the 
clearance of the drug. The fluctuations of the disease activity result, therefore, in variations 
in infliximab exposure, which are themselves responsible for fluctuations of the disease 
activity. The influence of several parameters reflecting the inflammation level on the 
clearance of infliximab has been reported in the literature. In particular, a positive 
correlation between CRP or disease activity and infliximab clearance has been evidenced14,17. 
Our results are in accordance with this knowledge. However, this influence was 
characterized using the baseline value of CRP and/or disease activity, and the follow-up of 
the patients was shorter. In the present study, we have used the clinical scores and the CRP 
as time-varying covariates. Thus, a CRP of 100 mg/L increased infliximab clearance by 21.6%. 
Partial Mayo scores of 3 and 10 resulted in an increase in the clearance of 10% and 25%, 
respectively. Conversely, there was no detectable influence of the Harvey Bradshaw Index 
(HBI) on infliximab clearance, probably because the HBI correlates poorly with mucosal 
inflammation18. Patients with UC had a 45.8% faster clearance, in line with a previous 
pharmacokinetic study19. Patients receiving azathioprine co-treatment had a 15.1% decrease 
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in infliximab clearance, which confirms previous reports on the effects of combotherapy20,21. 
This result may be explained by the immunosuppressive effects of azathioprine, which 
decrease the risk of immunisation to infliximab and the activity of the disease, and 
consequently the target-mediated elimination of infliximab. Similarly, there was a decrease 
in infliximab clearance following a dose increase, which was less expected. We hypothesized 
this was due to the improvement of the disease which led to less target-mediated 
elimination, rather than because of non-linearity of elimination. Of note, non-linearity was 
never reported in previous compartment models describing infliximab pharmacokinetics, 
which comforts our results. These different results emphasize the great influence of the 
disease activity on infliximab clearance, and they also underline the wide intra-individual 
variability of infliximab clearance throughout the treatment (figure 3). 
Additionally, previous studies have shown that the pharmacokinetics of monoclonal 
antibodies is time-dependent notably in cancer diseases22-24. There is less evidence in 
inflammatory diseases. It has been shown in adult IBD patients with maintenance infliximab 
treatment that there was a negative correlation between the number of infusions and 
infliximab trough concentrations, independently from CRP and clinical scores values, 
accordingly to our results25. In the present study, we modelled a slow linear increase in 
clearance with time, of 0.0348L/d per year of treatment in a typical subject. Other models 
such as the sigmoid Emax model, more physiological and used in previous studies, were 
tested. However, because the shape of the increase in clearance was very close to linear and 
because this reduced the number of parameters to estimate, a linear model was preferred. 
This slow increase in clearance was partially correlated to the increase of the body weight. 
Indeed, in some patients who lost weight, this linear increase was slower but still present. 
This was never reported before in compartment analysis, but it is important to remain aware 
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of this phenomenon, as it may contribute to explain some relapses in patients under long-
term maintenance treatment due to a slow evolution towards underexposure to infliximab. 
There was a possible, but not systematic, sharp change in clearance in some patients (11/93, 
11.8%). The logit-risk model used here to describe the fast changes in infliximab clearance 
was already tested in a cohort of children with IBD, and is useful to describe immunisations 
to infliximab as well as transient periods of higher clearance, for example during the 
induction phase 12. Of note, in the present study, only one patient tested positive to ADA. In 
this patient the logit-risk model detected a clearance increase of 1.9 fold prior to ADA 
positivity, indicating that the model described the immunization process well in this patient. 
The rate of immunization in the present cohort also may have been lower than in the 
general IBD population, because the patients were selected for treatment de-escalation. 
Eventually, the implementation of this complex pharmacokinetic model allowed precise 
estimations of infliximab trough concentrations, which was a pre-requisite for the second 
part of the study. The survival analysis showed that higher infliximab concentrations were 
strong predictors of the success of the de-escalation, with a threshold of 5.7 µg/mL before 
de-escalation and of 2.4 µg/mL at average after de-escalation. Consistently, the median 
trough concentration at the censure time was 2.2 µg/mL in relapsing patients, compared to 
5.5 µg/mL in the others (p<0.0001, Wilcoxon rank-sum test), which confirms the role of the 
exposure in the maintenance of the response. 
We chose to keep into the multivariate analysis only the average concentration after de-
escalation because the concentrations pre- and post-de-escalation were strongly correlated. 
This choice is questionable, but we felt that the concentration after de-escalation was more 
suited as it reflects the actual exposure to infliximab after the de-escalation, whatever the 
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concentration before the de-escalation, the individual pharmacokinetic characteristics 
and/or the modality of the de-escalation (dose, interval or mixed, with several possibilities of 
dose and/or interval modifications). However, in a typical subject, a 2-weeks increase in the 
infusion interval or a 2-fold decrease in the dose will approximately result in a 2-fold 
decrease in the trough after de-escalation, provided there is no disease flare or 
immunization that would result in increased clearance. Thus, in stable patients, de-
escalation can be considered if trough infliximab is above 5.7 µg/mL. 
A higher clearance and a higher linear increase in clearance were logically associated with an 
increased probability of relapse. These results support our hypothesis that measuring 
infliximab clearance could be of interest to improve the monitoring of the treatment12. A 
higher volume of distribution was also associated with lower relapse rates. This was 
unexpected as a higher volume of distribution would result in lower circulating 
concentrations. The trough concentration values at de-escalation in patients with a volume 
≥11.4L or <11.4L were not different though (p=0.08, Wilcoxon rank-sum test), because of the 
variability of the dose regimen and of the clearance values. This probably indicates that the 
effect of volume rather denotes a difference in the distribution process of infliximab. Thus, 
patients with a higher volume of distribution would have a higher tissue penetration with 
better efficacy of the drug, which could explain a lower risk of relapse after de-escalation. 
The other factors linked with a higher risk of relapse at de-escalation were UC diagnosis, 
current smoking, and a higher CRP at de-escalation. These last results are in line with the 
current knowledge of IBD, and are also very close to those reported previously in patients 
undergoing treatment escalation, were predictors of long-term response were CD diagnosis, 
non-smoking status and a normal CRP26. 
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The therapeutic implications of our results are multiple. First, the wide intra-individual 
variability of infliximab clearance warrants a pro-active TDM, in particular in case of disease 
flare, to ensure a sufficient exposure. Moreover, the slow increase in clearance we 
evidenced may lead to underexposure after several years of treatment even in patients in 
remission. Second, the use of TDM may help to a better selection of the patients eligible to 
de-escalation. Patients with CD, non-smokers, with low CRP are at lower risk of relapse, but 
the recourse to TDM increases the probability of success of de-escalation, by selecting only 
patients that have sufficient concentration before de-escalation (i.e. >5.7µg/mL). Multiple 
concentrations should be obtained after de-escalation to ensure a sufficient exposure, by 
maintaining trough concentrations above 2.4µg/mL. Ultimately, the measurement of 
clearance using compartment modelling may guide dosing adaptations at de-escalation. 
Indeed, lower increases in the dosing interval are required in “high clearers” to avoid 
underexposure. 
 
4. Conclusion
The results of this study show that the pharmacokinetics of infliximab in IBD adults varies 
with time. Clearance variations are closely related to the disease activity, the level of 
inflammation, and the treatment, but there are also unexplained variations such as a slow 
linear increase that remains only partially explained by body weight variations. Infliximab 
trough concentrations at de-escalation above 5.7 µg/mL and after de-escalation above 2.4 
µg/mL were associated with better clinical outcomes, as well as a lower clearance and a 
higher volume of distribution. Non-smoking, a diagnosis of CD and a low CRP at de-
escalation were also predictive of a better outcome. These results may help to the screening 
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of the patients eligible to de-escalation and physicians’ decision making, but also emphasize 
the need of a proactive drug monitoring of infliximab concentrations. A prospective 
assessment of model-based dosing adaptations to increase the probability of maintenance 
of the remission is now warranted. 
 
5. Patients and methods
5.1. Patients and study design. 
This was an observational, “real-world”, monocentric study, with a retrospective analysis of 
prospectively-recorded clinical and biological data. The database was approved by the 
“Commission Nationale Informatique et Libertés” (CNIL #1412467). The study included 91 
IBD adults treated with intravenous infliximab who needed treatment intensification to 
obtain remission, and who subsequently underwent a treatment de-escalation. The decision 
of de-escalation was taken by senior physicians experienced in the management of IBD. 
Patients were eligible to de-escalation if they were in clinical remission, defined as a HBI <4 
for CD or a partial Mayo score <2 for UC, and if they were in biological remission, defined as 
a CRP <5mg/L at the time of the evaluation. De-escalation consisted either of a dose 
reduction to a minimum of 5mg/kg of infliximab, and/or an increase in the interval between 
infusions of 1 to 4 weeks, to a maximum interval of 12 weeks. 
Infliximab trough concentrations were measured before and/or after de-escalation and/or 
along the treatment period at the discretion of the clinician, using a validated Enzyme-Linked 
Immunosorbent Assay (ELISA) method27. The detection of ADA was performed with an ELISA 
method previously described28. This ADA assay is “drug sensitive”, i.e. ADA cannot be 
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measured in the presence of infliximab, thus only sera with infliximab level <0.1 µg/mL were 
tested for ADA. 
Demographics and biologics were recorded at baseline and throughout follow-up at each 
infusion. The complete history of the treatment was retrieved as well. The clinical response 
after de-escalation was assessed by the HBI29 or the partial Mayo Score30 with respect to the 
IBD. The success of the de-escalation was defined as the absence of recurrence of clinical 
and/or endoscopic symptoms, as well as the absence of biological signs of underlying 
inflammation. Failure was defined as the necessity, based on the aforementioned criteria, to 
increase infliximab treatment or switch/swap to another treatment. The decision of 
considering the outcome of a de-escalation as a failure was taken by the physician in charge 
of the patient, who subsequently adapted the treatment to induce remission of the disease. 
 
5.2. Pharmacokinetic analysis 
Population pharmacokinetic modelling was performed using Monolix 4.3.3 (Lixsoft; Orsay, 
France). A one-compartment structural model with zero-order infusion and first-order 
elimination was implemented and parametrized in terms of clearance (CL) and central 
volume of distribution (V). Non-linear and mixed (linear and non-linear) eliminations were 
tested. The pharmacokinetic parameters were assumed to be log-normally distributed: 
   
Where    is the estimated individual parameter for the i
th patient,     is the typical value 
and  
 
 is the random effect for the ith patient. The values of  
 
 were assumed to be normally 
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distributed with a mean of 0 and a variance of   . For each parameter,  was fixed to 0 if 
the distribution of the  
 
 could not be estimated properly. 
Additive, proportional and combined additive-proportional residual error models were 
tested. The combined additive-proportional error model was implemented as follows: 
  
where and are observed and predicted jth measurements for the ith patient, 
respectively, and  and  are proportional and additive errors, with a mean of 0 
and variances of  and , respectively. 
 
5.3. Investigation of the effect of covariates 
The effect of the following covariates on the pharmacokinetic parameters was investigated: 
age, gender, body weight, body mass index (BMI), presence of ADA, haemoglobin, 
neutrophil count, lymphocyte count, CRP, disease (CD or UC) and corresponding activity 
scores (HBI and partial Mayo score, respectively), disease phenotype and age at diagnosis 
according to the Montreal classification, disease duration, infliximab therapy duration, 
previous treatment by adalimumab, 5-asa and/or glucocorticoids, concomitant use of 
azathioprine, prior bowel surgery, and tobacco use. Continuous covariates were power-
transformed and centred on their median: 
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where is the value of for a median subject, quantifies the influence of the 
covariate on  , and  is the median value of the covariate in the study population. 
The influence of categorical covariates was tested with respect to a reference category: 
where        is the value of in an arbitrary reference category and  quantifies the 
influence of the ith category on the value of . 
 
5.4. Modelling of the effects of the time-varying covariates 
The poor predictive performance of a simple 1-compartment model with static clearance 
suggested that infliximab pharmacokinetics varied with time, which was expected given the 
extended follow-up (median [min – max] of 3.75 [0.93 – 5.34] years). This was attributed to 
the variations of the activity of the disease and of the level of inflammation, disease flares, 
body weight variations and/or immunisation to infliximab. Therefore, CRP, body weight, BMI 
and clinical scores were tested as time-varying covariates. The influence of the co-treatment 
with azathioprine was tested as well, as a multiplicative factor on the clearance: 
Where  is the actual clearance of the ith individual,  is the clearance of the ith 
individual without azathioprine,  is a multiplicative factor that quantifies the 
influence of azathioprine co-treatment on , and  is an indicator variable taking 
the value 1 if azathioprine is present and 0 otherwise. As a first approach, the same type of 
equation was used to test the influence of ADA and of treatment intensification, defined as 
an increase of the dose of infliximab. 
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5.5. Modelling of the time-varying clearance of infliximab 
Despite the use of time-varying covariates, there were still important prediction errors. In 
particular, there was an overestimation bias that increased with time. As this was already 
reported before in non-compartment analysis 25 and suggested by the present data, a time-
varying clearance model was implemented that describes a linear increase in clearance with 
time: 
where  is the value of infliximab clearance of the ith individual at time t (in days), and 
    represents the absolute value of the clearance increase over a year. 
Nevertheless, there remained some changes in infliximab concentrations that could still not 
be described with the model above. There were obvious increases in clearance followed by 
very low concentrations, strongly suggesting the occurrence of an immunization, but without 
ADA evidenced. Therefore, a logit model was used to detect and describe the clearance 
variations that were not explained by the aforementioned time-varying model, as we 
previously reported 12. Briefly, this model is constituted of a linear risk function of time 
which is logit-transformed as follows: 
where and  denote the intercept and the slope of the risk function in the ith 
individual, respectively. The logit of the risk, ranging between 0 and 1, is then applied as a 
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power function of a multiplicative term (  ) that quantifies the magnitude of the 
clearance variation: 
   is assumed to be log-normally distributed and its typical value is assumed to be equal 
to 1, meaning that in a typical individual, no change in the clearance is observed. 
5.6. Model comparison and covariate selection 
The objective function was defined as the -2-log-likelihood (-2LL) and the OFV was used for 
model comparison and covariate selection. Nested and non-nested models were compared 
with the Likelihood Ratio Test (LRT) and AIC, defined as -2LL+2p (where p denotes the 
number of estimated parameters), respectively. 
The screening of the relevant time-varying covariates was performed before including the 
time-varying clearance described above, to avoid rejecting a significant covariate which 
effect would be inappropriately described by these time-varying functions. The effects of the 
static covariates were tested after implementing the effects of the time varying covariates 
and the time-varying clearance. Relevant covariates were selected using the LRT at the 
univariate step with a risk  of 10%, and were then retained in the full model if their 
removing resulted in a significant increase of the OFV at a risk  of 1%. The covariate 
selection was also based on the reduction of the unexplained variability of the parameters, 
and on the value of the Wald test that verifies whether the values of  or  are 
significantly different from 0. 
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The parameters were estimated using the Stochastic Approximation-Expectation 
Maximization (SAEM) algorithm with simulated annealing. The Relative Standard Errors (RSE) 
were calculated by stochastic approximation. The model comparison and selection 
procedures were also based on the inspection of the observed versus individual predicted 
concentrations, the distribution of the Individual Weighted Residuals, and the inspection of 
the predictions versus time plot. Prediction-corrected Visual Predictive Checks (VPC) were 
examined, based on 500 simulated replicates of the dataset. The individual parameters were 
determined by the Empirical Bayes Estimates (EBE) calculation and were used to estimate 
the values of the trough concentrations before each infusion. 
 
5.7. Investigation of the factors influencing the outcome of infliximab de-escalation 
A survival analysis was performed in order to investigate predictive factors of relapse. 
Because some patients had several consecutive de-escalations, an individual-clustered 
analysis with repeated events was used. The analysis was performed with Kaplan-Meier 
curves and univariate comparisons with the Wald test, which does not assume the 
independence of the observations within a cluster. The numerical variables were tested as 
continuous covariates and the trough concentration and pharmacokinetic parameters were 
also transformed into binomial covariates using recursive partitioning if they gave a p-value 
<0.05 under their continuous form. 
All the variables with univariate tests giving a p-value <0.2 were included in a multivariate 
Cox model. The final multivariate model was chosen after backward selection of significant 
uncorrelated variables. A p-value <0.05 was considered as significant. 
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Study Highlights 
 What is the current knowledge on this topic?
The pharmacokinetics and concentration-effect relationship of infliximab was never studied 
in IBD patients undergoing treatment de-escalation. Recent data suggest that the 
pharmacokinetic parameters, especially the clearance, may be predictive of the clinical 
response independently from trough concentration. 
 What question did this study address?
The pharmacokinetics of infliximab in IBD patients who underwent treatment de-escalation 
was described using a time-varying clearance model, and the value of trough concentrations 
and individual clearance in predicting the success of treatment de-escalation was explored. 
 What does this study add to our knowledge?
There is a wide intra-individual variability of infliximab pharmacokinetics in IBD patients, 
partially explained by disease-related parameters. Trough concentration and clearance 
before de-escalation, IBD type, tobacco use and CRP are strong predictors of relapse after 
de-escalation. 
 How might this change clinical pharmacology or translational science?
The results of this study suggest that monitoring the evolution of the clearance of the 
patients may help to monitor treatment efficacy and risk of relapse, being a reflection of the 
disease activity trough target-mediated drug disposition. 
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Table 1. Patients characteristics (n=91) 
Age at fisrt de-escalation (years) 36.9 (29.6 - 46.2) 
Male sex 39 (42.9) 
Weight at first de-escalation (kg) 66 (60 - 69) 
BMI at first de-escalation (kg/m²) 23.5 (21.2 - 26.6) 
Smoking 
 
Current smokers 17 (18.7) 
Ex-smokers 19 (20.9) 
Non-smokers 55 (60.4) 
Age  at diagnosis 
 
A1   <16 years 15 (16.5) 
A2   17 - 40 years 66 (72.5) 
A3   Over 40 years 10 (11.0) 
CD phenotype 62 (68.1) 
B1 Non-stricturing, non penetrating 43 (69.3) 
B2 Stricturing 12 (19.4) 
B3 Penetrating 7 (11.3) 
Perianeal disease (additional to B1, B2 or B3) 21 (33.9) 
L1 Ileal 10 (16.1) 
L2 Colonic 18 (29.1) 
L3 Ileocolonic 34 (54.8) 
L4 Upper disease (additional to L1, L2 or L3) 12 (19.4) 
UC phenotype 29 (31.9) 
E1 Ulcerative proctitis 5 (17.2) 
E2 Left-side UC 9 (31.0) 
E3 Extensive 15 (51.8) 
Disease duration at first de-escalation (years) 9.1 (4.1 - 14.5) 
Duration of infliximab therapy at fisrt de-escalation (years) 2.9 (1.5 - 6.0) 
Previous treatment by glucocorticoids 50 (54.9) 
Previous treatment by 5-asa 44 (48.4) 
Previous treatment by immunomodulators 57 (62.6) 
Previous treatment by adalimumab 12 (13.2) 
Previous bowel surgery 28 (30.8) 
De-escalation characteristics 
Total number of de-escalations 155 
Number of de-escalation per patient 1 (1 - 2) 
Type of de-escalation 
 
Dose reduction 35 (22.6) 
Infusion interval increase 114 (73.5) 
Mixed (dose and interval) 6 (3.9) 
Combination therapy at de-escalation 34 (21.9) 
  
 
 
Data are expressed as median (first quartile - third quartile) or number (percentage). Disease phenotype 
is described following the Montreal classification for inflammatory bowel diseases. 
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Table 2. Results of the pharmacokinetic analysis 
Parameter description Value 
Precision 
of the 
estimates 
(RSE %) 
Shrinkage 
(%) 
Fixed effects 
V (L) Volume of distribution 11.5 5 
CLbase (L.day
-1) Baseline clearance 0.273 7 
DiseaseUC Effect of disease on clearance (ref CD) 0.377 29 
CRP Effects of CRP on clearance 0.0654 15 
DOSE Effects of dose on clearance -0.267 22 
ActivityUC Effect of Mayo score (UC patients only) 0.0934 30 
factAZA Effect of azathioprine co-treatment on clearance 0.849 2 
slope (L.day-1.year-1) Linear clearance increase 0.0348 9 
WT Effects of weight variation on clearance increase 31.1 31 
baserisk Intercept (risk of immunization) 10.9 5 
beta Slope (risk of immunization) 0.0526 21 
CLvar Clearance variation magnitude 1 fixed 
 
Random effects 
V (%) BSV of the volume of distribution 25.4 15 49 
CL (%) BSV on the baseline clearance 44.3 10 18 
DOSE (%) BSV of the effects of the dose on clearance 33.3 19 45 
slope(%) BSV on the linear clearance increase 32.0 26 68 
beta (%) BSV of the slope (risk of immunization) 102.0 17 59 
CLvar (%) BSV of the clearance variation magnitude 40.4 11 23 
 
Residual error 
add (µg/mL) Additive error magnitude 0.446 22 
}13 
prop (%) Proportional error magnitude 20.6 6 
 
 
RSE: Relative Standard Error; BSV: Between-Subject Variability. 
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Table 3. Factors influencing the rate of relapse after infliximab de-escalation 
Variable Univariate analysis Multivariate analysis (Cox) 
 
HR (95% CI) p-value* HR (95% CI) p-value* 
Demographics and disease history and phenotype 
Age 1.00 (0.98 - 1.03) 0.69 
Male sex 1.40 (0.79 - 2.48) 0.25 
Tobacco (non-smokers versus current or former) 0.48 (0.27 - 0.85) 0.012 
Disease (UC versus CD) 1.32 (0.77 - 2.29) 0.31 
Disease and tobbaco 
 
CD, non-smoker (reference) 1 - 
 
CD, smoker or former 3.29 (1.52 - 7.15) 0.0026 
 
UC, non-smoker 2.34 (1.14 - 4.82) 0.021 
 
UC, smoker of former 2.82 (1.01 - 7.85) 0.048 
 
UC (all) + smokers with CD 2.77 (1.41 - 5.44) 0.0031 2.83 (1.29 - 6.23) 0.0093 
Age at diagnosis (<16 years versus ≥ 16 years) 0.31 (0.10 - 0.99) 0.047 
Previous treatment by glucocorticoids 1.09 (0.62 - 1.92) 0.77 
Previous treatment by 5-asa 1.33 (0.75 - 2.40) 0.34 
Previous treatment by immunomodulators 0.95 (0.52 - 1.75) 0.88 
Previous treatment by adalimumab 1.25 (0.60 - 2.57) 0.55 
Previous bowel surgery 1.30 (0.69 - 2.45) 0.42 
 Clinical and biological characteristics and treatments at the time of the de-escalation 
Disease duration 1.00 (0.96 - 1.05) 0.83 
Duration of infliximab therapy 0.98 (0.89 - 1.09) 0.76 
Clinical score ≥ 1 1.71 (0.85 - 3.42) 0.13 
CRP 1.06 (1.02 - 1.11) 0.0019 1.10 (1.04 - 1.17) 0.00064 
Heamoglobin 0.90 (0.69 - 1.17) 0.42 
Neutrophil count 1.00 (0.99 - 1.00) 0.67 
Lymphocytes count 0.72 (0.53 - 1.01) 0.059 
Immunomodulator use 1.19 (0.59 - 2.39) 0.62 
 Pharmacokinetic characteristics 
Volume of distribution (continuous) 0.81 (0.70 - 0.95) 0.0075 
Volume of distribution ≥ 11.4 L 0.33 (0.17 - 0.63) 0.00081 
Clearance at the time of the de-escalation 
(continuous) 38.73 (8.11 - 185) <0.0001 
Clearance at the time of the de-escalation ≥ 0.31 L/h 5.83 (2.16 - 15.8) 0.00050 
Slope of linear clearance increase (continuous)a 1.01 (1.01 - 1.03) <0.0001 
Slope of linear clearance increase ≥ 0.032 L/d/y 1.16 (0.64 - 2.08) 0.63 
Infliximab trough at de-escalation (continuous) 0.94 (0.90 - 0.99) 0.014 
Infliximab trough at de-escalation ≥ 5.7 µg/mL 0.34 (0.21 - 0.57) <0.0001 
Average trough after de-escalation (continuous) 0.86 (0.74 - 1.00) 0.051 
Average trough after de-escalation ≥ 2.4 µg/mL 0.20 (0.12 - 0.33) <0.0001 0.27 (0.14 - 0.52) 0.00010 
Infliximab trough at censure time (continuous) 0.85 (0.74 - 0.98) 0.023 
Infliximab trough at censure time ≥ 2.2 µg/mL 0.22 (0.13 - 0.36) <0.0001 
  
 
 
HR: Hazard ratio ; 95% CI: 95% confidence interval. * Wald test. 
a
HR is given for slope x 1000, to avoid unreadable values of HR and IC95 due to the 
small values of the slope. 
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Figures Legends 
Figure 1. Diagnostic plots. A. Observed versus population-predicted concentrations. B. 
Observed versus individually-predicted concentrations. C. Individual weighted residuals 
versus time. D. Distribution of the individual weighted residuals. 
Figure 2. Visual Predictive Checks. The grey shaded areas represent the 90% confidence 
interval of the predictions at the 5, 50 and 95e percentile. The full lines represents the 5, 50 
and 95e percentile of the observations. Open circles are the observed concentrations. 
Figure 3. Representative individual fits. The full line represents the individually-predicted 
concentration versus time. Open circles are the observed concentrations. The dashed line 
represents the value of the clearance versus time (the values of the clearance are reported 
on the right-handed axis). The patient on the upper-right was tested positive to ADA at time 
455. 
Figure 4. Kaplan Meyer curves for probability of sustained remission after de-escalation. 
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